Skip to main content
Erschienen in: Rheumatology International 9/2006

01.07.2006 | Case Report

Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature

verfasst von: Soner Senel, Emin Kaya, Ismet Aydogdu, M. Ali Erkurt, Irfan Kuku

Erschienen in: Rheumatology International | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

We report four patients with rheumatic disease (RD) and chronic myelogenous leukemia (CML). In two patients with Behcet’s disease (BD) and rheumatoid arthritis (RA), CML developed after RD, in two patients with diffuse cutaneous systemic sclerosis and spondyloarthropathy, RD was diagnosed after CML. A variety of interactions have been described between hematological malignancies and RD. Nevertheless, few cases of RD have been documented associated with CML. It is unclear whether the development of CML in patients with RD and RD development after CML occurs by chance alone, is due to the underlying disease, or is facilitated by drugs. Whatever the cause is, it should be kept in mind that CML may develop in the course of RD and RD may be seen in CML patients.
Literatur
1.
Zurück zum Zitat Sillaber C, Mayerhofer M, Agis H, et al. (2003) Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr 115:485–504PubMedCrossRef Sillaber C, Mayerhofer M, Agis H, et al. (2003) Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr 115:485–504PubMedCrossRef
2.
Zurück zum Zitat Valeriano J (1997) Malignancy and rheumatic disease. Cancer Control 3:236–244 Valeriano J (1997) Malignancy and rheumatic disease. Cancer Control 3:236–244
3.
Zurück zum Zitat Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502CrossRefPubMed Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502CrossRefPubMed
4.
Zurück zum Zitat Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, et al. (1991)The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, et al. (1991)The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef
5.
Zurück zum Zitat Kataria RK, Brent LH (2004) Spondyloarthropathies. Am Fam Physician 69:2853–2860PubMed Kataria RK, Brent LH (2004) Spondyloarthropathies. Am Fam Physician 69:2853–2860PubMed
6.
Zurück zum Zitat Karincaoglu Y, Kaya E, Esrefoglu M, Aydogdu I (2003) Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet’s disease. Leuk Lymphoma 44:1063–1065CrossRefPubMed Karincaoglu Y, Kaya E, Esrefoglu M, Aydogdu I (2003) Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet’s disease. Leuk Lymphoma 44:1063–1065CrossRefPubMed
7.
Zurück zum Zitat Budak-Alpdogan T, Alpdogan O, Direskeneli H, et al. (1998) Skin hyperreactivity of Behçet’s patients (pathergy reactıon) is also positive in interferon alpha-treated chronic myeloid leukemia patients, indicating similarly altered neuthrophil functions in both disorders. Br J Rheumatol 37:1148–1151CrossRefPubMed Budak-Alpdogan T, Alpdogan O, Direskeneli H, et al. (1998) Skin hyperreactivity of Behçet’s patients (pathergy reactıon) is also positive in interferon alpha-treated chronic myeloid leukemia patients, indicating similarly altered neuthrophil functions in both disorders. Br J Rheumatol 37:1148–1151CrossRefPubMed
8.
Zurück zum Zitat Budak-Alpdogan T, Demircay Z, Alpdogan O, et al. (1997) Behcet’s disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behcet’s symptoms. Ann Hematol 74:45–48CrossRefPubMed Budak-Alpdogan T, Demircay Z, Alpdogan O, et al. (1997) Behcet’s disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behcet’s symptoms. Ann Hematol 74:45–48CrossRefPubMed
9.
Zurück zum Zitat Raanani P, Ben-Bassat I (2002) Immune-mediated complications during ınterferon therapy in hematological patients. Acta Haematologica 107:133–144CrossRefPubMed Raanani P, Ben-Bassat I (2002) Immune-mediated complications during ınterferon therapy in hematological patients. Acta Haematologica 107:133–144CrossRefPubMed
10.
Zurück zum Zitat Sacchi S, Talpaz M (1995) Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401–2407PubMed Sacchi S, Talpaz M (1995) Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401–2407PubMed
11.
Zurück zum Zitat Abe T, Imai K, Tokunoh T et al (1995) Case report: rheumatoid arthritis complicated by chronic myelogenous leukemia treated with interferon. Nihon Rinsho Meneki Gakkai Kaishi 18:70–75PubMed Abe T, Imai K, Tokunoh T et al (1995) Case report: rheumatoid arthritis complicated by chronic myelogenous leukemia treated with interferon. Nihon Rinsho Meneki Gakkai Kaishi 18:70–75PubMed
12.
Zurück zum Zitat Pointud P, Prudat M, Peron JM (1993) Acute leukemia after low dose methotrexate therapy in apatient with rheumatoid arthritis. J Rheumatol 20:1215–1216PubMed Pointud P, Prudat M, Peron JM (1993) Acute leukemia after low dose methotrexate therapy in apatient with rheumatoid arthritis. J Rheumatol 20:1215–1216PubMed
13.
Zurück zum Zitat Dubin Kerr L, Troy K, Isola L (1995) Temporal association between the use of methotrexate and development of leukemia in two patients with rheumatoid arthritis. J Rheumatol 22:2356–2358PubMed Dubin Kerr L, Troy K, Isola L (1995) Temporal association between the use of methotrexate and development of leukemia in two patients with rheumatoid arthritis. J Rheumatol 22:2356–2358PubMed
14.
Zurück zum Zitat Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC, Jun JB (2005) Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int May 25(4):311–313CrossRef Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC, Jun JB (2005) Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int May 25(4):311–313CrossRef
15.
Zurück zum Zitat Job-Deslandre C, Menkes CJ, Michalski B, et al. (1985) Rheumatoid polyarthritis, gougerot-sjogren syndrome and chronic myeloid leukemia. Apropos of two cases. Rev Rhum Mal Osteoartic 52:247–249 Job-Deslandre C, Menkes CJ, Michalski B, et al. (1985) Rheumatoid polyarthritis, gougerot-sjogren syndrome and chronic myeloid leukemia. Apropos of two cases. Rev Rhum Mal Osteoartic 52:247–249
16.
Zurück zum Zitat Miyachi K, Ihara A, Hankins RW, et al. (2003) Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 22:329–332CrossRefPubMed Miyachi K, Ihara A, Hankins RW, et al. (2003) Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 22:329–332CrossRefPubMed
17.
Zurück zum Zitat Kotter I, Muller CA, Einsele H, et al. (1999) Interferon-alpha-associated polyarthritis Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature. Z Rheumatol 58:185–195 Kotter I, Muller CA, Einsele H, et al. (1999) Interferon-alpha-associated polyarthritis Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature. Z Rheumatol 58:185–195
18.
Zurück zum Zitat Georgescu L, Quinn G, Schwartzman S, Paget S (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804CrossRefPubMed Georgescu L, Quinn G, Schwartzman S, Paget S (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804CrossRefPubMed
19.
Zurück zum Zitat Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB (1991) Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 18:809–814PubMed Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB (1991) Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 18:809–814PubMed
20.
Zurück zum Zitat Moder K, Tefferi A, Cohen M, Menke D, Luthra H (1995) Hematologic malignanices and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99:276–281CrossRefPubMed Moder K, Tefferi A, Cohen M, Menke D, Luthra H (1995) Hematologic malignanices and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99:276–281CrossRefPubMed
21.
Zurück zum Zitat Bleyer A (1998) Methotrexate induced lymphoma?. J Rheumatol 25:404–406PubMed Bleyer A (1998) Methotrexate induced lymphoma?. J Rheumatol 25:404–406PubMed
22.
23.
Zurück zum Zitat Watanabe S, Sugihara T, Takahashi M, et al. (1994) Concordant improvement of progressive systemic sclerosis and chronic myelogenous leukemia with interferon-alpha treatment. Rinsho Ketsueki 35:895–897PubMed Watanabe S, Sugihara T, Takahashi M, et al. (1994) Concordant improvement of progressive systemic sclerosis and chronic myelogenous leukemia with interferon-alpha treatment. Rinsho Ketsueki 35:895–897PubMed
24.
Zurück zum Zitat Wooten MD, Scott JW, Miller AM, et al. (1998) Chronic myelogenous leukemia and porphyria cutanea tarda in a patient with limited systemic sclerosis. South Med J 91:493–495PubMed Wooten MD, Scott JW, Miller AM, et al. (1998) Chronic myelogenous leukemia and porphyria cutanea tarda in a patient with limited systemic sclerosis. South Med J 91:493–495PubMed
25.
Zurück zum Zitat Beretta L, Caronni M, Vanoli M, et al. (2002) Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol 147:385–386CrossRefPubMed Beretta L, Caronni M, Vanoli M, et al. (2002) Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol 147:385–386CrossRefPubMed
Metadaten
Titel
Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature
verfasst von
Soner Senel
Emin Kaya
Ismet Aydogdu
M. Ali Erkurt
Irfan Kuku
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 9/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0100-5

Weitere Artikel der Ausgabe 9/2006

Rheumatology International 9/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.